Summit Financial LLC Has $2.38 Million Stock Holdings in Pfizer Inc. $PFE

Key Points

• Summit Financial LLC increased its stake in Pfizer Inc. by 19.9%, acquiring an additional 15,582 shares to bring its total holdings to 93,727 shares, valued at approximately $2.375 million.
• Pfizer reported a quarterly earnings per share (EPS) of $0.78, exceeding expectations by $0.20, with revenues of $14.65 billion, a year-over-year increase of 10.3%.
• The company recently announced a quarterly dividend of $0.43, yielding 6.7%, with a payout ratio of 91.49% for its stockholders of record.

Summit Financial LLC lifted its holdings in Pfizer Inc. (NYSE:PFE - Free Report) by 19.9% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 93,727 shares of the biopharmaceutical company's stock after purchasing an additional 15,582 shares during the period. Summit Financial LLC's holdings in Pfizer were worth $2,375,000 at the end of the most recent reporting period.

Other hedge funds also recently made changes to their positions in the company. Clarity Asset Management Inc. acquired a new position in shares of Pfizer in the 4th quarter worth approximately $27,000. Gould Capital LLC boosted its holdings in shares of Pfizer by 97.2% in the fourth quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the period. GKV Capital Management Co. Inc. acquired a new position in shares of Pfizer in the first quarter worth about $27,000. North Capital Inc. acquired a new position in shares of Pfizer in the first quarter worth about $28,000. Finally, Bayforest Capital Ltd acquired a new position in shares of Pfizer in the first quarter worth about $28,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Down 2.8%

Shares of PFE stock traded down $0.73 during trading on Monday, hitting $25.15. 32,304,503 shares of the company were exchanged, compared to its average volume of 45,249,543. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.85 and a current ratio of 1.16. The firm has a market capitalization of $142.99 billion, a price-to-earnings ratio of 13.38, a P/E/G ratio of 0.92 and a beta of 0.52. The business's 50-day simple moving average is $24.70 and its 200 day simple moving average is $24.39. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43.

Pfizer (NYSE:PFE - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. The business had revenue of $14.65 billion during the quarter, compared to analysts' expectations of $13.43 billion. Pfizer had a net margin of 16.84% and a return on equity of 21.42%. The firm's quarterly revenue was up 10.3% compared to the same quarter last year. During the same period last year, the company posted $0.60 earnings per share. Pfizer has set its FY 2025 guidance at 2.900-3.100 EPS. As a group, analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Shareholders of record on Friday, July 25th will be paid a $0.43 dividend. The ex-dividend date is Friday, July 25th. This represents a $1.72 dividend on an annualized basis and a yield of 6.8%. Pfizer's payout ratio is 91.49%.

Wall Street Analyst Weigh In

Several research analysts have commented on PFE shares. Leerink Partners decreased their target price on shares of Pfizer from $28.00 to $26.00 and set a "market perform" rating for the company in a report on Wednesday, April 30th. Bank of America raised their target price on shares of Pfizer from $27.00 to $28.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. UBS Group raised their target price on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a report on Wednesday, April 30th. Citigroup raised their target price on shares of Pfizer from $25.00 to $26.00 and gave the stock a "neutral" rating in a report on Wednesday, August 6th. Finally, Morgan Stanley raised their price target on shares of Pfizer from $32.00 to $33.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 6th. Two analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, eleven have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $28.12.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.